+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Radioimmunoassays Market - Global Forecast 2026-2032- Product Image
Radioimmunoassays Market - Global Forecast 2026-2032- Product Image
Sale

Radioimmunoassays Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012225
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Radioimmunoassays Market is projected to reach USD 1.35 Billion in 2026. It is expected to continue growing at a CAGR of 4.40%, reaching USD 1.76 Billion by 2032.

Radioimmunoassays remain a highly sensitive analytical technique for quantifying hormones, therapeutic drugs, enzymes, vitamins, tumor markers, and infectious disease-related biomarkers in biological samples. Built on the specificity of antigen-antibody binding and the detectability of radioisotope-labeled tracers, radioimmunoassay testing has historically supported endocrinology, oncology, nephrology, reproductive medicine, toxicology, and pharmaceutical research. Despite the broad adoption of non-radioactive immunoassays, radioimmunoassays continue to be relevant where exceptional analytical sensitivity, well-characterized protocols, and validated longitudinal datasets are essential. Demand is shaped by clinical laboratory modernization, continued biomarker research, regulated diagnostic workflows, and the need for reliable quantification of low-abundance analytes. At the same time, the technique operates within strict radiation safety, radioactive waste management, and quality assurance requirements, making operational excellence a central factor for laboratories and research institutions using radioimmunoassay platforms.

Transformative Shifts in the Radioimmunoassay Landscape

The radioimmunoassay landscape is being reshaped by the migration of many routine assays toward chemiluminescent, fluorescent, and enzyme-linked immunoassay formats, while radioimmunoassays retain utility in specialized and legacy-validated applications. Laboratories are increasingly prioritizing automation, sample traceability, radiation dose reduction, and standardized quality control to maintain compliance and reproducibility. Regulatory expectations for in vitro diagnostics, laboratory-developed tests, radioactive material handling, and bioanalytical validation are also influencing assay selection and operational design. A major shift is the growing emphasis on biomarker specificity and clinical relevance, especially in endocrine disorders, oncology research, and therapeutic drug monitoring, where assay performance must be demonstrated through precision, accuracy, linearity, recovery, and interference testing. In parallel, supply chain controls for radioisotopes, cold-chain reagents, antibodies, calibrators, and control materials are becoming more important as laboratories seek continuity, assay comparability, and reduced variability across testing sites.

Cumulative Impact of Artificial Intelligence on Radioimmunoassays

Artificial intelligence is influencing radioimmunoassays primarily through laboratory informatics, quality management, and data interpretation rather than through the radioactive detection chemistry itself. AI-enabled analytics can support anomaly detection in calibration curves, flag shifts in control performance, identify pipetting or incubation-related deviations, and improve review of longitudinal assay data. In research settings, machine learning is increasingly used to correlate radioimmunoassay-derived biomarker measurements with clinical, genomic, imaging, and pharmacokinetic datasets, enabling deeper interpretation of endocrine, metabolic, oncology, and immunology studies. AI can also strengthen workflow planning by forecasting reagent usage, monitoring instrument utilization, and improving turnaround-time management, while digital audit trails enhance compliance with laboratory quality systems. However, AI adoption in radioimmunoassay environments must be governed by validation, explainability, cybersecurity, data integrity, and human oversight, particularly when results contribute to patient care or regulated bioanalytical studies.

Key Regional Insights for Radioimmunoassays

Asia-Pacific is a significant environment for radioimmunoassays due to expanding diagnostic infrastructure, high patient volumes, growing endocrine and oncology testing needs, and strong academic research activity across advanced and emerging healthcare systems. Europe benefits from advanced quality frameworks, strong nuclear safety oversight, extensive clinical research capacity, and harmonized in vitro diagnostic expectations, while the transition toward non-radioactive alternatives is balanced by continued use of validated radioimmunoassay methods in specialized applications. North America is characterized by mature clinical laboratory networks, stringent radioactive material controls, established bioanalytical research practices, and strong demand for validated specialty testing in endocrinology, oncology, fertility assessment, and therapeutic monitoring. Latin America continues to rely on a mix of centralized reference laboratories, public health institutions, and academic centers, with radioimmunoassay use shaped by reagent availability, regulatory import requirements, and the need for cost-effective biomarker testing. Africa presents diverse adoption patterns, with leading academic and reference laboratories supporting specialized testing, while broader deployment is influenced by equipment access, trained personnel, radioactive waste management capabilities, accreditation coverage, and supply chain reliability. The Middle East is seeing increased investment in hospital-based diagnostics, specialty laboratories, and chronic disease management, supporting selective use of advanced immunoassay technologies where radiation regulation, infrastructure readiness, and quality systems permit.

Key Group Insights for Radioimmunoassay Adoption

NATO member countries include several highly regulated diagnostics markets where nuclear safety, laboratory accreditation, emergency preparedness, and biosecurity frameworks shape procurement, operation, transport, and disposal practices associated with radioimmunoassay testing. G7 countries generally demonstrate mature laboratory governance, robust research ecosystems, strong clinical chemistry expertise, and rigorous quality assurance requirements, supporting radioimmunoassay use in niche, validated, and research-intensive workflows. BRICS economies combine large patient populations, expanding biomedical research, and increasing diagnostic modernization, creating sustained interest in reliable immunoassay methods while also accelerating transitions to automated non-radioactive platforms. The European Union’s regulatory environment emphasizes in vitro diagnostic performance, traceability, radiation protection, data integrity, and laboratory quality systems, encouraging rigorous assay validation and careful justification of radioactive methods. ASEAN countries show rising relevance for radioimmunoassay and broader immunoassay testing as healthcare systems expand specialist diagnostics, maternal health programs, endocrine testing, and clinical research capacity, although adoption varies by laboratory accreditation and radiation regulatory readiness. The GCC is strengthening advanced diagnostic capabilities through investment in tertiary care, precision medicine programs, chronic disease management, and centralized laboratory infrastructure, with radioimmunoassays positioned for specialized applications requiring validated sensitivity and controlled workflows.

Key Country Insights for Radioimmunoassays

China and India are important environments for biomarker testing due to large populations, expanding hospital networks, chronic disease burdens, and strong research activity, although laboratories increasingly compare radioimmunoassays with high-throughput non-radioactive technologies. The United States remains a major center for specialized radioimmunoassay applications due to advanced reference laboratories, established clinical research networks, and strict controls over radioactive materials and diagnostic quality. Japan and South Korea have advanced diagnostic sectors, strong quality expectations, and significant biomedical research capacity, supporting specialized radioimmunoassay use where sensitivity, low-abundance analyte detection, and validated protocols are critical. Germany, the United Kingdom, France, Italy, and Spain operate within mature diagnostic and research systems where radioimmunoassays are used selectively when validated performance or historical comparability is required, while regulatory pressure and operational safety considerations encourage alternatives for routine workflows. Australia’s adoption is concentrated in accredited laboratories and research institutions, supported by strong radiation safety governance and emphasis on analytical quality. Canada’s use is supported by hospital laboratories, academic medicine, and regulated nuclear safety practices, with emphasis on validated testing and centralized expertise. Russia maintains scientific and clinical laboratory capabilities relevant to radioisotope-based assays, with adoption shaped by domestic healthcare structures, reagent availability, and regulatory controls. Brazil and Mexico reflect growing demand for endocrine, oncology, fertility, and infectious disease-related immunoassay testing, with radioimmunoassay adoption influenced by specialized laboratory capacity, import processes, and reagent access.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay quality, regulatory compliance, and operational resilience to sustain radioimmunoassay relevance in specialized diagnostics and research. Laboratories should strengthen radiation safety programs, staff competency assessments, radioactive waste procedures, and audit-ready documentation. Decision-makers should evaluate each assay based on clinical utility, analytical sensitivity, historical comparability, reagent stability, and availability of validated non-radioactive alternatives. Investment in laboratory information systems, automated data capture, AI-assisted quality control, and digital chain-of-custody tools can reduce errors and improve traceability. Procurement teams should diversify critical reagent sourcing where feasible, assess radioisotope supply risks, and maintain validated contingency protocols. Research institutions should harmonize pre-analytical procedures, calibration practices, and control materials to improve reproducibility across studies. For long-term competitiveness, organizations should position radioimmunoassays as part of a broader immunoassay strategy that integrates specialized legacy methods with modern automated platforms.

Research Methodology

The research methodology for evaluating radioimmunoassays should combine verified secondary research, primary expert validation, and structured analytical review. Secondary sources include regulatory guidance, laboratory accreditation standards, radiation protection frameworks, peer-reviewed clinical chemistry literature, pharmacokinetic and biomarker validation guidance, and public health laboratory references. Primary inputs should be gathered from clinical laboratory directors, nuclear medicine and radiation safety professionals, immunoassay scientists, procurement specialists, and bioanalytical researchers to validate practical adoption patterns and operational constraints. The analysis should examine assay applications, sample types, isotope handling requirements, quality control practices, regulatory obligations, and technology substitution trends. Triangulation across scientific publications, regulatory documents, and expert interviews helps ensure reliability. The methodology should exclude unsupported assumptions and avoid speculative market sizing, instead emphasizing documented use cases, technology performance considerations, regulatory context, and evidence-based adoption factors.

Conclusion

Radioimmunoassays continue to hold value in clinical diagnostics, pharmaceutical research, and biomarker science where high sensitivity, validated protocols, and long-term assay comparability are critical. The field is evolving within a broader immunoassay ecosystem increasingly defined by automation, AI-enabled quality management, regulatory scrutiny, and the shift toward non-radioactive alternatives for routine testing. Regional, group, and country-level adoption depends on healthcare infrastructure, laboratory accreditation, radiation safety capability, reagent access, and research intensity. Organizations that maintain rigorous validation, strong compliance systems, resilient supply chains, and digitally enabled workflows will be best positioned to preserve the benefits of radioimmunoassay technology while adapting to modern laboratory expectations.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Radioimmunoassays Market, by Product Type
7.1. Introduction
7.2. Reagents & Kits
7.3. Antibodies
7.3.1. Monoclonal Antibodies
7.3.2. Polyclonal Antibodies
7.4. Radioisotopes / Radiolabeled Tracers
7.4.1. Iodine-125
7.4.2. Iodine-131
7.4.3. Tritium
7.4.4. Carbon-14
7.5. Instruments & Analyzers
7.5.1. Gamma Counters
7.5.2. Liquid Scintillation Counters
7.5.3. Automated RIA Analyzers
8. Radioimmunoassays Market, by End User
8.1. Introduction
8.2. Diagnostic Laboratories
8.2.1. Hospital Laboratories
8.2.2. Independent Laboratories
8.3. Hospitals
8.3.1. Private Hospitals
8.3.2. Public Hospitals
8.4. Research Institutes
8.4.1. Academic Institutions
8.4.2. Pharmaceutical Companies
9. Radioimmunoassays Market, by Sample Type
9.1. Introduction
9.2. Blood Serum
9.3. Plasma
9.4. Urine
9.5. Saliva
10. Radioimmunoassays Market, by Region
10.1. Asia-Pacific
10.2. Europe
10.3. North America
10.4. Latin America
10.5. Africa
10.6. Middle East
11. Radioimmunoassays Market, by Group
11.1. NATO
11.2. G7
11.3. BRICS
11.4. European Union
11.5. ASEAN
11.6. GCC
12. Radioimmunoassays Market, by Country
12.1. China
12.2. United States
12.3. Japan
12.4. India
12.5. Germany
12.6. United Kingdom
12.7. Australia
12.8. France
12.9. South Korea
12.10. Italy
12.11. Canada
12.12. Russia
12.13. Brazil
12.14. Mexico
12.15. Spain
13. Competitive Landscape
13.1. Market Share Analysis, 2025
13.2. FPNV Positioning Matrix, 2025
13.3. Market Concentration Analysis, 2025
13.3.1. Concentration Ratio (CR)
13.3.2. Herfindahl Hirschman Index (HHI)
13.4. Recent Developments & Impact Analysis, 2025
13.5. Product Portfolio Analysis, 2025
13.6. Benchmarking Analysis, 2025
14. Company Profiles
14.1. Abbexa Limited
14.2. Abcam Plc
14.3. ALPCO
14.4. Antigenix America, Inc.
14.5. Berthold Technologies GmbH & Co.KG
14.6. Biosynth Ltd
14.7. BioVendor - Laboratorni medicina a.s.
14.8. Creative Biomart, Inc.
14.9. Danaher Corporation
14.10. Demeditec Diagnostics GmbH
14.11. Diasorine S.P.A.
14.12. DRG International, Inc.
14.13. Drive DeVilbiss International
14.14. EUROIMMUN Medizinische Labordiagnostika AG
14.15. Hidex Oy.
14.16. IBL International GmbH
14.17. Immuno-Biological Laboratories, Inc.
14.18. LKB Instruments
14.19. LubioScience GmbH
14.20. Marin Biologic Laboratories, Inc.
14.21. Merck & Co, Inc
14.22. Montreal Biotech Inc.
14.23. MP Biomedicals, LLC
14.24. NovoLytix GmbH
14.25. Padyab Teb Co.
14.26. PerkinElmer Inc.
List of Figures
FIGURE 1. GLOBAL RADIOIMMUNOASSAYS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RADIOIMMUNOASSAYS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RADIOIMMUNOASSAYS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RADIOIMMUNOASSAYS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RADIOIMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 19. GLOBAL RADIOIMMUNOASSAYS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RADIOIMMUNOASSAYS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL POLYCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL POLYCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL POLYCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL RADIOISOTOPES / RADIOLABELED TRACERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL RADIOISOTOPES / RADIOLABELED TRACERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL RADIOISOTOPES / RADIOLABELED TRACERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IODINE-125 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IODINE-125 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IODINE-125 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL IODINE-131 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL IODINE-131 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL IODINE-131 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TRITIUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TRITIUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TRITIUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CARBON-14 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CARBON-14 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CARBON-14 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GAMMA COUNTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL GAMMA COUNTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL GAMMA COUNTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LIQUID SCINTILLATION COUNTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LIQUID SCINTILLATION COUNTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LIQUID SCINTILLATION COUNTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL AUTOMATED RIA ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL AUTOMATED RIA ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL AUTOMATED RIA ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BLOOD SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL BLOOD SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL BLOOD SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 95. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 97. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 98. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 99. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 100. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 102. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 103. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 104. EUROPE RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 125. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 127. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 128. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 129. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 130. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 132. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 133. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 134. AFRICA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 148. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 149. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 150. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 151. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 153. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 154. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 155. NATO RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 156. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 158. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 159. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 160. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 161. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 163. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 164. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 165. G7 RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 166. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 168. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 169. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 170. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 171. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 173. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 174. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 175. BRICS RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 186. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 188. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 189. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 190. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 191. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 193. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 194. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 195. ASEAN RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 196. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 197. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 198. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 199. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 200. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 201. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 203. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 204. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 205. GCC RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 206. GLOBAL RADIOIMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 207. CHINA RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 209. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 210. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 211. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 212. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 214. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 215. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 216. CHINA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 227. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 230. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 231. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 232. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 234. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 235. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 236. JAPAN RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 237. INDIA RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 239. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 240. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 241. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 242. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 244. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 245. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 246. INDIA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 247. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 249. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 250. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 251. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 252. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 254. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 255. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 256. GERMANY RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 267. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 269. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 270. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 271. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 272. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 275. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 276. AUSTRALIA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 277. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 279. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 280. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 281. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 282. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 284. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 285. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 286. FRANCE RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 287. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 289. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 290. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 291. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 292. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 294. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 295. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 296. SOUTH KOREA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 297. ITALY RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 299. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 300. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 301. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 302. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 304. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 305. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 306. ITALY RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 307. CANADA RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 309. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 310. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 311. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 312. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 314. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 315. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 316. CANADA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 324. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 325. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 326. RUSSIA RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 327. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 328. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 329. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 330. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 331. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 332. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 334. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 335. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 336. BRAZIL RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 337. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 338. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 339. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 340. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 341. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 342. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 343. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 344. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 345. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 346. MEXICO RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 347. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 348. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 349. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 350. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY RADIOISOTOPES / RADIOLABELED TRACERS, 2017-2032 (USD MILLION)
TABLE 351. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2017-2032 (USD MILLION)
TABLE 352. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 353. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2017-2032 (USD MILLION)
TABLE 354. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 355. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 356. SPAIN RADIOIMMUNOASSAYS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 357. GLOBAL RADIOIMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 358. GLOBAL RADIOIMMUNOASSAYS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbexa Limited
  • Abcam Plc
  • ALPCO
  • Antigenix America, Inc.
  • Berthold Technologies GmbH & Co.KG
  • Biosynth Ltd
  • BioVendor – Laboratorni medicina a.s.
  • Creative Biomart, Inc.
  • Danaher Corporation
  • Demeditec Diagnostics GmbH
  • Diasorine S.P.A.
  • DRG International, Inc.
  • Drive DeVilbiss International
  • EUROIMMUN Medizinische Labordiagnostika AG
  • Hidex Oy.
  • IBL International GmbH
  • Immuno-Biological Laboratories, Inc.
  • LKB Instruments
  • LubioScience GmbH
  • Marin Biologic Laboratories, Inc.
  • Merck & Co, Inc
  • Montreal Biotech Inc.
  • MP Biomedicals, LLC
  • NovoLytix GmbH
  • Padyab Teb Co.
  • PerkinElmer Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.35 Billion
Forecasted Market Value ( USD ) by 2032 $ 1.76 Billion
Compound Annual Growth Rate4.4%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Radioimmunoassays - Global Strategic Business Report - Product Image

Radioimmunoassays - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
2026 Radioimmunoassay Market Outlook: Size, Share, Growth Trends and Forecast 2025-2034 - Product Image

2026 Radioimmunoassay Market Outlook: Size, Share, Growth Trends and Forecast 2025-2034

  • Report
  • 160 Pages
  • Global
From
2025 Global Forecast for Radioimmunoassays Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Radioimmunoassays Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Cardiac Marker Analyzer Market Outlook 2026-2034: Market Share, and Growth Analysis by Type of Analyzers (Immuno-Fluorescence Analyzers (IFA), Radioimmunoassay (RIA) Analyzers, Enzyme Immunoassay (EIA) Analyzers, Other Type of Analyzers), End-Users - Product Image

Cardiac Marker Analyzer Market Outlook 2026-2034: Market Share, and Growth Analysis by Type of Analyzers (Immuno-Fluorescence Analyzers (IFA), Radioimmunoassay (RIA) Analyzers, Enzyme Immunoassay (EIA) Analyzers, Other Type of Analyzers), End-Users

  • Report
  • 160 Pages
  • Global
From
United States Radioimmunoassay Market Report by Product, Application, End User, States and Company Analysis, 2025-2033 - Product Image

United States Radioimmunoassay Market Report by Product, Application, End User, States and Company Analysis, 2025-2033

  • Report
  • 200 Pages
  • United States
From

About the Radioimmunoassay Market

Radioimmunoassay (RIA) is a laboratory technique used to measure the concentration of antigens, such as hormones, in a sample. In the context of oncology drugs, RIA is used to measure the concentration of tumor markers in the blood, which can help diagnose and monitor cancer. RIA can also be used to measure the concentration of therapeutic drugs in the blood, which can help determine the effectiveness of a drug and its dosage. RIA is a highly sensitive and specific technique, and is used in many clinical laboratories. It is also used in research laboratories to study the pharmacokinetics of drugs, and to develop new drugs. In the oncology drug market, RIA is used to measure the concentration of therapeutic drugs in the blood, and to monitor the effectiveness of the drug. It is also used to measure the concentration of tumor markers in the blood, which can help diagnose and monitor cancer. Some companies in the RIA market for oncology drugs include Abbott Laboratories, Beckman Coulter, Siemens Healthcare, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.